ERBB2 and breast carcinoma: As reported in the PERMEATE study, the CNS‐ORR of pyrotinib combined with capecitabine in breast cancer patients with BM reached 76.9%, further confirming the effectiveness of pyrotinib in the patients with HER2‐positive breast cancer and BM.41